1. No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3.
- Author
-
Hanatani, Tadaaki, Fukuda, Tsuyoshi, Onishi, Sachi, Funae, Yoshihiko, and Azuma, Junichi
- Subjects
- *
ENZYMES , *METABOLISM , *DICLOFENAC , *ANTI-inflammatory agents , *HYPOGLYCEMIC agents , *COUMARINS , *WARFARIN - Abstract
Objective. CYP2C9 is a polymorphic enzyme, and CYP2C9*3 is associated with decreased metabolic activity. In addition to the impaired metabolism, we investigated whether the CYP2C9*3 exhibited altered inhibitory susceptibility compared with CYP2C9*1. Method. In the present study, CYP2C9.1 and CYP2C9.3 were expressed in yeast. Using typical CYP2C9 substrates (diclofenac, tolbutamide and S-warfarin) and a potent CYP2C9 inhibitor (nicardipine), the Ki values for nicardipine on the three metabolisms in CYP2C9*1 and CYP2C9*3 were determined. Result. The ratios of Ki (CYP2C9*3) /Ki (CYP2C9*1) on tolbutamide, diclofenac and S-warfarin metabolisms were 1.2, 3.1 and 0.8, respectively. Conclusion. In conclusion, there are no significant differences in the inhibitory susceptibility between the two CYP2C9 enzymes. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF